Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, MA, United States of America; Department of Psychiatry, Harvard Medical School, Boston, MA, United States of America.
Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, United States of America.
Psychoneuroendocrinology. 2021 Jul;129:105243. doi: 10.1016/j.psyneuen.2021.105243. Epub 2021 Apr 28.
Avoidant/restrictive food intake disorder (ARFID) is characterized by restrictive eating and failure to meet nutritional needs but is distinct from anorexia nervosa (AN) because restriction is not motivated by weight/shape concerns. We examined levels of orexigenic ghrelin and anorexigenic peptide YY (PYY) in young females with ARFID, AN and healthy controls (HC).
94 females (22 low-weight ARFID, 40 typical/atypical AN, and 32 HC ages 10-22 years) underwent fasting blood draws for total ghrelin and total PYY. A subset also provided blood 30, 60 and 120 min after a standardized meal.
Females with ARFID ate less than those with AN or HC (ps<0.012); were younger (14.4 ± 3.2 years) than those with AN (18.9 ± 3.1 years) and HC (17.4 ± 3.1 years) (ps<0.003) and at a lower Tanner stage (3.1 ± 1.5) than AN (4.5 ± 1.1;) and HC (4.4 ± 1.1; ps<0.005), but did not differ in BMI percentiles or BMI Z-scores from AN (ps>0.44). Fasting and postprandial ghrelin were lower in ARFID versus AN (ps≤.015), but not HC (ps≥0.62). Fasting and postprandial PYY did not differ between ARFID versus AN or HC (ps≥0.13); ARFID did not demonstrate the sustained high PYY levels post-meal observed in those with AN and HC. Secondary analyses controlling age or Tanner stage and calories consumed showed similar results. Exploratory analyses suggest that the timing of the PYY peak in ARFID is earlier than HC, showing a peak PYY level 30 min post-meal (p = .037).
ARFID and AN appear to have distinct patterns of secretion of gut-derived appetite-regulating hormones that may aid in differential diagnosis and provide new treatment targets.
回避/限制型进食障碍(ARFID)的特征是进食受限且无法满足营养需求,但与神经性厌食症(AN)不同,因为限制饮食不是出于对体重/体型的担忧。我们检查了 ARFID、AN 和健康对照组(HC)年轻女性的食欲肽 ghrelin 和厌食肽 PYY 的水平。
94 名女性(22 名低体重 ARFID、40 名典型/非典型 AN 和 32 名 HC,年龄 10-22 岁)进行禁食血液检测,以检测总 ghrelin 和总 PYY。亚组还在标准化餐后 30、60 和 120 分钟提供血液。
ARFID 组女性的食量少于 AN 组或 HC 组(p<0.012);年龄小于 AN 组(18.9±3.1 岁)和 HC 组(17.4±3.1 岁)(p<0.003),且 Tanner 分期较低(3.1±1.5)比 AN 组(4.5±1.1)和 HC 组(4.4±1.1)(p<0.005),但与 AN 组(p>0.44)相比,ARFID 组的 BMI 百分位数或 BMI Z 分数没有差异。与 AN 组相比,ARFID 组的空腹和餐后 ghrelin 水平较低(p≤.015),但与 HC 组相比则没有差异(p≥0.62)。与 AN 组或 HC 组相比,ARFID 组的空腹和餐后 PYY 没有差异(p≥0.13);ARFID 组在餐后没有表现出 AN 和 HC 中观察到的持续高 PYY 水平。控制年龄或 Tanner 分期和摄入卡路里的二次分析显示出相似的结果。探索性分析表明,ARFID 中 PYY 峰值的时间早于 HC,表现为餐后 30 分钟时 PYY 水平达到峰值(p=0.037)。
ARFID 和 AN 似乎具有不同的肠道来源食欲调节激素分泌模式,这可能有助于鉴别诊断,并提供新的治疗靶点。